RU2017126990A - Замещенные бензольные соединения - Google Patents
Замещенные бензольные соединения Download PDFInfo
- Publication number
- RU2017126990A RU2017126990A RU2017126990A RU2017126990A RU2017126990A RU 2017126990 A RU2017126990 A RU 2017126990A RU 2017126990 A RU2017126990 A RU 2017126990A RU 2017126990 A RU2017126990 A RU 2017126990A RU 2017126990 A RU2017126990 A RU 2017126990A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- membered heterocycloalkyl
- compound according
- halogen
- cycloalkyl
- Prior art date
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical class C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 81
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 71
- 229910052736 halogen Inorganic materials 0.000 claims 59
- -1 C 1 -C 6 alkoxyl Chemical group 0.000 claims 55
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 54
- 150000002367 halogens Chemical class 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 34
- 125000004093 cyano group Chemical group *C#N 0.000 claims 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 29
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 29
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 26
- 229910052799 carbon Inorganic materials 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 17
- 125000004043 oxo group Chemical group O=* 0.000 claims 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 14
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 6
- 125000002393 azetidinyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000003566 oxetanyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 3
- FZNGSNUBJOVDRX-UHFFFAOYSA-N 3,5-diacetamido-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]benzamide Chemical compound CC(=O)NC1=CC(NC(C)=O)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C1 FZNGSNUBJOVDRX-UHFFFAOYSA-N 0.000 claims 3
- CJPMZAQWTRKEEE-UHFFFAOYSA-N 3-bromo-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-5-methoxy-4-propoxybenzamide Chemical compound C1=C(OC)C(OCCC)=C(Br)C=C1C(=O)NCC1=C(C)C=C(C)NC1=O CJPMZAQWTRKEEE-UHFFFAOYSA-N 0.000 claims 3
- QOSIYIZOWFDFTH-UHFFFAOYSA-N 3-chloro-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-4-hydroxy-5-methoxybenzamide Chemical compound ClC1=C(O)C(OC)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C1 QOSIYIZOWFDFTH-UHFFFAOYSA-N 0.000 claims 3
- FWRVYJLUPPGAOX-UHFFFAOYSA-N 4-(2-amino-2-oxoethoxy)-3-chloro-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-5-methoxybenzamide Chemical compound ClC1=C(OCC(N)=O)C(OC)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C1 FWRVYJLUPPGAOX-UHFFFAOYSA-N 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- JFEXNEMJRIPESK-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3,5-dimethoxybenzamide Chemical compound COC1=CC(OC)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C1 JFEXNEMJRIPESK-UHFFFAOYSA-N 0.000 claims 3
- CJOOKLCQRFMKCZ-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-(2,2-dimethylpropanoylamino)benzamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC=CC(NC(=O)C(C)(C)C)=C1 CJOOKLCQRFMKCZ-UHFFFAOYSA-N 0.000 claims 3
- DYBOTOAIZGPJFS-UHFFFAOYSA-N n-[5-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methylcarbamoyl]-2-methylphenyl]furan-2-carboxamide Chemical compound O=C1NC(C)=CC(C)=C1CNC(=O)C1=CC=C(C)C(NC(=O)C=2OC=CC=2)=C1 DYBOTOAIZGPJFS-UHFFFAOYSA-N 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- ZHBSEXHHJLGRKX-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C1 ZHBSEXHHJLGRKX-UHFFFAOYSA-N 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 229910003827 NRaRb Inorganic materials 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- JJLKTTCRRLHVGL-UHFFFAOYSA-L [acetyloxy(dibutyl)stannyl] acetate Chemical compound CC([O-])=O.CC([O-])=O.CCCC[Sn+2]CCCC JJLKTTCRRLHVGL-UHFFFAOYSA-L 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- BAQLUVXNKOTTHU-UHFFFAOYSA-N metofenazate Chemical compound COC1=C(OC)C(OC)=CC(C(=O)OCCN2CCN(CCCN3C4=CC(Cl)=CC=C4SC4=CC=CC=C43)CC2)=C1 BAQLUVXNKOTTHU-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- WWKVFWLVVSEMCQ-UHFFFAOYSA-N spiro[1h-2-benzofuran-3,1'-cyclohexane] Chemical compound C12=CC=CC=C2COC21CCCCC2 WWKVFWLVVSEMCQ-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474825P | 2011-04-13 | 2011-04-13 | |
| US61/474,825 | 2011-04-13 | ||
| US201161505676P | 2011-07-08 | 2011-07-08 | |
| US61/505,676 | 2011-07-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013150510A Division RU2629118C2 (ru) | 2011-04-13 | 2012-04-13 | Замещенные бензольные соединения |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017126990A true RU2017126990A (ru) | 2019-02-01 |
| RU2017126990A3 RU2017126990A3 (enExample) | 2020-10-30 |
Family
ID=46000399
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013150510A RU2629118C2 (ru) | 2011-04-13 | 2012-04-13 | Замещенные бензольные соединения |
| RU2017126990A RU2017126990A (ru) | 2011-04-13 | 2012-04-13 | Замещенные бензольные соединения |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013150510A RU2629118C2 (ru) | 2011-04-13 | 2012-04-13 | Замещенные бензольные соединения |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9376422B2 (enExample) |
| EP (3) | EP3165520B1 (enExample) |
| JP (1) | JP2014513084A (enExample) |
| KR (1) | KR101975613B1 (enExample) |
| CN (1) | CN104066718B (enExample) |
| AR (1) | AR086839A1 (enExample) |
| AU (2) | AU2012242604B2 (enExample) |
| BR (1) | BR112013026308B1 (enExample) |
| CA (1) | CA2832846C (enExample) |
| DK (1) | DK2697198T3 (enExample) |
| ES (1) | ES2590489T3 (enExample) |
| HK (1) | HK1202534A1 (enExample) |
| HU (1) | HUE030722T2 (enExample) |
| IL (1) | IL228746B (enExample) |
| MX (1) | MX344530B (enExample) |
| PL (1) | PL2697198T3 (enExample) |
| PT (1) | PT2697198T (enExample) |
| RU (2) | RU2629118C2 (enExample) |
| TW (2) | TW201733984A (enExample) |
| WO (1) | WO2012142513A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| WO2013075084A1 (en) * | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| IL308807B2 (en) | 2012-04-13 | 2025-08-01 | Epizyme Inc | Combination therapy for treating cancer |
| DK3184523T3 (da) | 2012-04-13 | 2019-08-19 | Epizyme Inc | N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system. |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| US20150239842A1 (en) * | 2012-09-28 | 2015-08-27 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
| PE20150886A1 (es) * | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
| CN110898067A (zh) * | 2012-10-15 | 2020-03-24 | Epizyme股份有限公司 | 癌症治疗方法 |
| TWI494424B (zh) * | 2012-11-20 | 2015-08-01 | Dow Global Technologies Llc | 可蒸餾燃料標記物 |
| BR112015014090A2 (pt) * | 2012-12-13 | 2017-07-11 | Glaxosmithkline Llc | intensificador de inibidores de zeste homólogo 2 |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| US20150344427A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone compounds |
| AU2013361079B2 (en) | 2012-12-21 | 2018-07-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| BR112015022785A2 (pt) | 2013-03-14 | 2017-07-18 | Epizyme Inc | composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt |
| US9765035B2 (en) | 2013-03-14 | 2017-09-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153100A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014153090A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives asprmt1 inhibitors and uses thereof |
| WO2014178954A1 (en) | 2013-03-14 | 2014-11-06 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| WO2014144659A1 (en) | 2013-03-14 | 2014-09-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| RS59790B1 (sr) | 2013-03-15 | 2020-02-28 | G1 Therapeutics Inc | Privremena zaštita normalnih ćelija tokom hemoterapije |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| EP2970281A4 (en) * | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BENZOL COMPOUNDS |
| ES2717680T3 (es) | 2013-04-30 | 2019-06-24 | Glaxosmithkline Ip No 2 Ltd | Potenciador de inhibidores del homólogo de Zeste 2 |
| US9556157B2 (en) | 2013-07-10 | 2017-01-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010049A1 (en) * | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| SG11201602269QA (en) | 2013-10-16 | 2016-04-28 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| WO2015077193A1 (en) * | 2013-11-19 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| CN116019921A (zh) | 2013-12-06 | 2023-04-28 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| PE20161552A1 (es) | 2014-06-17 | 2017-01-11 | Pfizer | Compuestos de dihidroisoquinolinona sustituida |
| PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| WO2015200650A1 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| CN106794177A (zh) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| RU2017118165A (ru) * | 2014-10-28 | 2018-11-29 | Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед | Ингибиторы энхансера гомолога 2 zestes |
| BR112017010166A2 (en) | 2014-11-17 | 2018-02-14 | Epizyme, Inc. | solid tumor treatment method, activity inhibition method, oral dosage form for treating a solid tumor, solid pharmaceutical formulation, process for preparing a pharmaceutical formulation, and solid pharmaceutical composition |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US20180271857A1 (en) | 2014-12-23 | 2018-09-27 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| CN108135908A (zh) | 2015-04-20 | 2018-06-08 | Epizyme股份有限公司 | 用于治疗癌症的组合疗法 |
| WO2016187394A1 (en) * | 2015-05-19 | 2016-11-24 | Van Wijnen Andre J | Methods and materials for promoting bone formation |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| CA2996412A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| LT3378859T (lt) * | 2015-11-19 | 2020-01-27 | Jiangsu Hengrui Medicine Co., Ltd. | Benzofurano darinys, jo gavimo būdas ir jo panaudojimas medicinoje |
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| CA3011186A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2017251555B2 (en) * | 2016-04-14 | 2021-04-29 | Guangzhou Joyo Pharmatech Co., Ltd | Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases |
| JP7121660B2 (ja) | 2016-06-01 | 2022-08-18 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| WO2017218953A1 (en) | 2016-06-17 | 2017-12-21 | Epizyme, Inc. | Ezh2 inhibitors for treating cancer |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CN108314677B (zh) * | 2017-01-17 | 2020-06-30 | 安徽中科拓苒药物科学研究有限公司 | 一种ezh2抑制剂及其用途 |
| US11214561B2 (en) | 2017-01-25 | 2022-01-04 | Ancureall Pharmaceutical (Shanghai) Co., Ltd. | Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN110621316B (zh) * | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| JP7257328B2 (ja) | 2017-05-18 | 2023-04-13 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | ベンゾフラン誘導体遊離塩基の結晶およびその製造方法 |
| US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| WO2019050924A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | POLY THERAPY FOR THE TREATMENT OF CANCER |
| WO2019091450A1 (zh) | 2017-11-10 | 2019-05-16 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃衍生物的制备方法 |
| WO2019097369A1 (en) | 2017-11-14 | 2019-05-23 | Pfizer Inc. | Ezh2 inhibitor combination therapies |
| WO2019152419A1 (en) | 2018-01-31 | 2019-08-08 | Mirati Therapeutics, Inc | Prc2 inhibitors |
| JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのｐｒｃ２サブユニットの阻害 |
| JP7411256B2 (ja) * | 2018-07-27 | 2024-01-11 | エボポイント、バイオサイエンシズ、カンパニー、リミテッド | 多置換ベンゼン環化合物、製造方法及びその用途 |
| MX2021007536A (es) | 2018-12-21 | 2021-09-23 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo. |
| WO2020192652A1 (zh) | 2019-03-25 | 2020-10-01 | 上海华汇拓医药科技有限公司 | 酰胺类化合物制备方法及其在医药领域的应用 |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| WO2020247475A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| GB201908453D0 (en) * | 2019-06-12 | 2019-07-24 | Enterprise Therapeutics Ltd | Compounds for treating respiratory disease |
| US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
| CN113248481B (zh) * | 2021-04-19 | 2023-03-24 | 中山大学 | Ezh2共价不可逆抑制剂、制备方法及其用途 |
| CN113292489B (zh) * | 2021-06-16 | 2022-08-30 | 泓博智源(开原)药业有限公司 | 二氯代二烷基烟腈的制备方法 |
| IL317228A (en) | 2022-06-13 | 2025-01-01 | Treeline Biosciences Inc | BCL6 quinolone bifunctional joints |
| CA3258412A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | HETEROBORCTIONAL BCL6 DEGRADING AGENTS 1,8-NAPHTHYRIDIN-2-ONE |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| CN1118595A (zh) | 1993-12-27 | 1996-03-13 | 卫材株式会社 | 氨茴酸衍生物 |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| JP2002525352A (ja) | 1998-09-30 | 2002-08-13 | ザ、プロクター、エンド、ギャンブル、カンパニー | ２−置換ケトアミド |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| CA2433158C (en) | 2000-12-28 | 2011-05-10 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| ATE447971T1 (de) | 2002-02-19 | 2009-11-15 | Shionogi & Co | Antipruriginosa |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| TWI324926B (en) * | 2004-04-23 | 2010-05-21 | Bristol Myers Squibb Co | Monocyclic heterocycles as kinase inhibitors |
| EP1765994B1 (en) | 2004-06-01 | 2009-11-18 | The University of North Carolina at Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| ATE494548T1 (de) | 2005-06-02 | 2011-01-15 | Univ North Carolina | Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DK1940821T3 (da) | 2005-10-19 | 2013-06-10 | Gruenenthal Gmbh | Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler. |
| NZ567000A (en) | 2005-10-21 | 2010-03-26 | Merck & Co Inc | Potassium channel inhibitors |
| US20090203057A1 (en) | 2005-10-28 | 2009-08-13 | Yi Zhang | Protein demethylases comprising a jmjc domain |
| EP1966141A1 (en) | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| AU2006336552B2 (en) | 2006-01-20 | 2012-12-20 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| RU2008149246A (ru) | 2006-05-15 | 2010-06-20 | Айрм Ллк (Bm) | Соединение на основе терефталата, композиции и их применение в качестве ингибиторов интегразы вич |
| WO2007136592A2 (en) * | 2006-05-18 | 2007-11-29 | Amphora Discovery Corporation | 2-0x0-l,2-dihydr0quin0line derivatives, compositions, and uses thereof as antiproliferative agents |
| EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTECTIVE COMPOSITIONS AND CORRESPONDING METHODS |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| US8247401B2 (en) | 2007-10-31 | 2012-08-21 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| JP5511680B2 (ja) | 2007-12-19 | 2014-06-04 | キャンサー・リサーチ・テクノロジー・リミテッド | ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用 |
| CN101977905B (zh) | 2008-01-23 | 2014-07-02 | 百时美施贵宝公司 | 4-吡啶酮化合物及其对于癌症的用途 |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| US8299093B2 (en) * | 2008-08-08 | 2012-10-30 | New York Blood Center, Inc. | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| CA2738583A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| JP2012522013A (ja) | 2009-03-27 | 2012-09-20 | ザ ユーエービー リサーチ ファウンデーション | 調節ｉｒｅｓ媒介翻訳 |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| CA2784899A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| PH12012502194A1 (en) | 2010-05-07 | 2014-09-05 | Glaxosmithkline Llc | Indoles |
| ES2534804T3 (es) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| ES2607064T3 (es) | 2010-12-01 | 2017-03-29 | Glaxosmithkline Llc | Indoles |
| BR112013013668A2 (pt) | 2010-12-03 | 2016-09-06 | Epizyme Inc | moduladores 7-deazapurina de histona metiltransferase, e métodos de uso dos mesmos |
| EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| EP2727328B8 (en) | 2011-06-28 | 2020-02-26 | NCR Corporation | Image processing to prevent access to private information |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| PE20150886A1 (es) | 2012-10-15 | 2015-06-04 | Epizyme Inc | Compuestos de benceno sustituidos |
-
2012
- 2012-04-12 TW TW106103833A patent/TW201733984A/zh unknown
- 2012-04-12 TW TW101112996A patent/TWI598336B/zh active
- 2012-04-13 PT PT127169688T patent/PT2697198T/pt unknown
- 2012-04-13 PL PL12716968.8T patent/PL2697198T3/pl unknown
- 2012-04-13 AU AU2012242604A patent/AU2012242604B2/en not_active Ceased
- 2012-04-13 KR KR1020137029686A patent/KR101975613B1/ko active Active
- 2012-04-13 WO PCT/US2012/033662 patent/WO2012142513A1/en not_active Ceased
- 2012-04-13 EP EP16173275.5A patent/EP3165520B1/en active Active
- 2012-04-13 US US14/110,873 patent/US9376422B2/en active Active
- 2012-04-13 CN CN201280029120.3A patent/CN104066718B/zh active Active
- 2012-04-13 ES ES12716968.8T patent/ES2590489T3/es active Active
- 2012-04-13 CA CA2832846A patent/CA2832846C/en active Active
- 2012-04-13 AR ARP120101289A patent/AR086839A1/es unknown
- 2012-04-13 EP EP18189032.8A patent/EP3470396A1/en not_active Withdrawn
- 2012-04-13 RU RU2013150510A patent/RU2629118C2/ru active
- 2012-04-13 JP JP2014505375A patent/JP2014513084A/ja active Pending
- 2012-04-13 DK DK12716968.8T patent/DK2697198T3/en active
- 2012-04-13 BR BR112013026308-3A patent/BR112013026308B1/pt active IP Right Grant
- 2012-04-13 EP EP12716968.8A patent/EP2697198B1/en active Active
- 2012-04-13 RU RU2017126990A patent/RU2017126990A/ru not_active Application Discontinuation
- 2012-04-13 HU HUE12716968A patent/HUE030722T2/en unknown
- 2012-04-13 MX MX2013011922A patent/MX344530B/es active IP Right Grant
- 2012-04-13 HK HK15103015.8A patent/HK1202534A1/xx unknown
-
2013
- 2013-10-06 IL IL228746A patent/IL228746B/en active IP Right Grant
-
2016
- 2016-05-23 US US15/162,453 patent/US20160332969A1/en not_active Abandoned
-
2017
- 2017-08-21 AU AU2017218920A patent/AU2017218920A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017126990A (ru) | Замещенные бензольные соединения | |
| RU2018103944A (ru) | Производные этинила как модуляторы метаботропного рецептора глутамата | |
| AR045651A1 (es) | Derivados de tiazol como moduladores del receptor de cannabinoide | |
| MX2015017343A (es) | Derivados de pirrolopiridina o pirazolopiridina. | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| AR114064A2 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| RU2009106866A (ru) | Спирокетальное производное с конденсированными кольцами и его применение в качестве противодиабетического лекарственного средства | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| JP2014513084A5 (enExample) | ||
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| RU2006141842A (ru) | Конденсированное хинолиновое производное и его применение | |
| RU2018146946A (ru) | Химические соединения | |
| RU2014149183A (ru) | Проницаемые ингибиторы гликозидазы и их применения | |
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| ME02490B (me) | Hemijska jedinjenja | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| JP2014516931A5 (enExample) | ||
| CA2647036A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20141000A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210505 |